NCT05171387View on ClinicalTrials.gov

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

December 4, 2024

Study Completion Date

February 24, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide 600 mg twice daily

The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.

DRUG

Androgen deprivation therapy (ADT)

Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY